The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv

Journal of Molecular Medicine

Volumn 76, Issue 6, 1998, Pages 451-458

  Grim, Jon ^a,b,c,d,f   Deshane, Jessy ^f   Siegal, Gene P ^f   Alvarez, Ronald D ^e,f,g   DiFiore, Paolo ^h   Curiel, David T ^f  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Arthr and Musculoskel Dis Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Jeanne Ann Griffin Women's Cancer R ^*

^e Dept of Obstetrics and Gynecology   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g AMERICAN COLLEGE OF SURGEONS   (United States)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Apoptosis; erbB2; Her2 Neu; Single chain antibody; Tumor cells

Indexed keywords

CELL ANTIBODY; PROTEIN SFV; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MOLECULAR CLONING; ONCOGENE C ERB; OVARY CARCINOMA; PREDICTION; PROTEIN EXPRESSION;

ANTIBODIES; APOPTOSIS; CARCINOMA; FEMALE; GENE TRANSFER TECHNIQUES; GENES, ERBB-2; HELA CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN FRAGMENTS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031979392     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050237     Document Type: Article

References (36)

1. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI (1994) The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109-2123
2. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182
3. Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159-7163
4. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP (1996) Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, cell proliferation characteristics in non-small cell lung cancer cells lines. Cancer Res 56:206-209
5. Stumm G, Eberwein S, Rostock-Wolf S, Stein H, Pomer S, Schlegel J, Waldherr R (1996) Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 69:17-22
6. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA, Chung LW (1996) Transfected neu oncogene induces human prostate cancer metastasis. Prostate 28:73-83
7. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-82
10. Dougall WC, Greene MI (1994) Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. Cell Biophysics 25:209-218
11. Ebbinghaus SW, Gee JE, Rodu B, Mayfield CA, Sanders G, Miller DM (1993) Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest 92:2433-2439
12. Noonberg SB, Scott GK, Hunt CA, Hogan ME, Benz CC (1994) Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. Gene 149: 123-126
13. Wiechen K, Dietel M (1995) c-erbB-2 anti-sense phosphorothioate oligodeoxyribonucleotides inhibit growth and serum-induced cell spreading P185c-erbB-2-overexpressing ovarian carcinoma cells. Int J Cancer 63:604-608
14. Bertram J, Killian M, Brysch W, Schlingensiepen K H, Kneba M (1994) Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem Biophys Res Comm 200:661-667
15. Colomer R, Lupu R, Bacus SS, Gelmann EP (1994) erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Canc 70: 819-825
16. Chen SY, Marasco WA (1996) Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol 23:148-153
17. Beerli RR, Wels W, Hynes NE (1994) Intracellular expression of single chain antibodies reverts erbB-2 transformation. J Biol Chem 269:23931-23936
18. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT (1994) Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1:332-337
19. Deshane J, Grim J, Loechel F, Siegal GP, Alvarez RD, Curiel DT (1996) Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 3:89-98
20. Deshane J, Siegal GP, Alvarez RD, Wang M, Feng M, Cabrera G, Liu T, Kay M, Curiel DT (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96: 2980-2989
21. Baserga R (1994) Oncogenes and the strategy of growth factors. Cell 79:927-930
22. Di Fiore PP, Segatto O, Lonardo F, Fazioli F, Pierce JH, Aaronson SA (1990) The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity Mol Cell Biol 10:2749-2756
23. Curiel DT (1994) High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. Nat Immun 13:141-164
24. Curiel DT, Wagner E, Cotten M, Birnstiel ML, Agarwal S, Li CM, Loechel S, Hu PC (1992) High-efficiency gene transfer mediated by adneovirus coupled to DNA-polylysine complexes. Hum Gene Ther 3:147-154
25. Grim J, Deshane J, Feng M, Lieber A, Kay M, Curiel DT (1996) ErbB-2 knockout employing an intracellular single chain antibody (sFv) accomplishes specific toxicity in erbB-2 expressing lung cancer cells. Am J Resp Cell Mol Bio 15:348-354
26. Kim M, Wright M, Deshane J, Accavitti M, Tilden A, Saleh M, Vaughan WP, Carabasi M H, Rogers MD, Hockett RD, Grizzle WE, Curiel DT (1996) A novel gene therapy strategy tor elimination of prostate carcinoma cells from human bone marrow. Hum Gene Ther 8:157-170
27. Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT (1997) An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast cancer cells overexpressing erbB-2. Gene Ther 4:317-322
28. Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T, Pelicci PG (1993) She products are substrates of erbB-2 kinase. Oncogene 8:2105-2512
29. Segatto O, Lonardo F, Helin K, Wexler D, Fazioli F, Rhee SG, Di Fiore PP (1992) erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling. Oncogene 7:1339-1346
30. Barnes MN, Deshane JS, Siegal GP, Alvarez RD, Curiel DT (1996) Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell sensitivity. Clin Canter Res 2:1089-1095
31. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA (1995) Phenotypic knockout of the high affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci USA 92:3137-3141
32. Graus-Porta D, Beerli RR, Hynes NE (1995) Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15:1182-1191
33. Carraway KR, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8
34. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP (1990) The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 2:992-1003
35. Beerli RR, Wels W, Hynes NE (1994) Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Comm 204:666-672
36. Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE (1996) Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13: 275-282